🇺🇸 HyperCVAD in United States
7 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 7
Most-reported reactions
- Acute Lymphocytic Leukaemia Refractory — 1 report (14.29%)
- Electrocardiogram Qt Prolonged — 1 report (14.29%)
- Fatigue — 1 report (14.29%)
- Platelet Count Abnormal — 1 report (14.29%)
- Pleural Effusion — 1 report (14.29%)
- Sinus Tachycardia — 1 report (14.29%)
- Supraventricular Tachycardia — 1 report (14.29%)
Other Oncology approved in United States
Frequently asked questions
Is HyperCVAD approved in United States?
HyperCVAD does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for HyperCVAD in United States?
Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.